Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q1 EPS by 44c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $86.95 +0.46%
EPS Growth %: +4.8%
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +4.8%
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($1.24), $0.44 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $3.55 million versus the consensus estimate of $37.66 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- Akari Therapeutics adds oncology expert Patricia LoRusso to advisory board
- Cosmos Health posts 31% revenue gain in Q2 and H1 2026
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
